Cara Therapeutic Stock Buy Hold or Sell Recommendation
| CARA Stock | USD 0.69 0.04 5.48% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cara Therapeutic is 'Strong Sell'. Macroaxis provides Cara Therapeutic buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CARA positions. The advice algorithm takes into account all of Cara Therapeutic's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Cara Therapeutic's buy or sell advice are summarized below:
Real Value 4.07 | Target Price 14.29 | Hype Value 0.71 | Market Value 0.69 | Naive Value 0.66 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Cara Therapeutic given historical horizon and risk tolerance towards Cara Therapeutic. When Macroaxis issues a 'buy' or 'sell' recommendation for Cara Therapeutic, the advice is generated through an automated system that utilizes algorithms and statistical models.
Cara |
Execute Cara Therapeutic Buy or Sell Advice
The Cara recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cara Therapeutic. Macroaxis does not own or have any residual interests in Cara Therapeutic or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cara Therapeutic's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cara Therapeutic Trading Alerts and Improvement Suggestions
| Cara Therapeutic is way too risky over 90 days horizon | |
| Cara Therapeutic has some characteristics of a very speculative penny stock | |
| Cara Therapeutic appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 20.97 M. Net Loss for the year was (118.51 M) with loss before overhead, payroll, taxes, and interest of (56.14 M). | |
| Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cara Therapeutic has a strong financial position based on the latest SEC filings | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 30000 shares by Makara Richard of Cara Therapeutic at 18.93 subject to Rule 16b-3 |
Cara Therapeutic Returns Distribution Density
The distribution of Cara Therapeutic's historical returns is an attempt to chart the uncertainty of Cara Therapeutic's future price movements. The chart of the probability distribution of Cara Therapeutic daily returns describes the distribution of returns around its average expected value. We use Cara Therapeutic price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cara Therapeutic returns is essential to provide solid investment advice for Cara Therapeutic.
| Mean Return | 0.60 | Value At Risk | -9 | Potential Upside | 13.75 | Standard Deviation | 6.94 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cara Therapeutic historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cara Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cara Therapeutic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cara Therapeutic backward and forwards among themselves. Cara Therapeutic's institutional investor refers to the entity that pools money to purchase Cara Therapeutic's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2023-12-31 | 644.8 K | Verition Fund Managegment, Llc | 2023-12-31 | 550 K | Two Sigma Advisers, Llc | 2023-12-31 | 514.2 K | Millennium Management Llc | 2023-12-31 | 467.2 K | Goldman Sachs Group Inc | 2023-12-31 | 419.7 K | Northern Trust Corp | 2023-12-31 | 391.8 K | Acadian Asset Management Llc | 2023-12-31 | 360.5 K | Stifel Financial Corp | 2023-12-31 | 313.1 K | Two Sigma Investments Llc | 2023-12-31 | 307.3 K | Blackrock Inc | 2023-12-31 | 3.6 M | Vanguard Group Inc | 2023-12-31 | 2.6 M |
Cara Therapeutic Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 2.9M | 13.4M | (18.2M) | 50.3M | (12.0M) | (11.4M) | |
| Free Cash Flow | (109.2M) | (5.8M) | (60.1M) | (78.8M) | (94.5M) | (89.7M) | |
| Depreciation | 370K | 198K | 209K | 248K | 259K | 498.1K | |
| Other Non Cash Items | 4.6M | 806K | 1.3M | 1.7M | 5.6M | 5.9M | |
| Capital Expenditures | 18K | 349K | 39K | 43K | 2.4M | 2.5M | |
| Net Income | (106.4M) | 8.4M | (88.4M) | (85.5M) | (118.5M) | (112.6M) | |
| End Period Cash Flow | 18.7M | 32.1M | 13.9M | 64.1M | 52.2M | 54.8M | |
| Change To Inventory | (2.6M) | 197K | 277K | 201K | (438K) | (459.9K) | |
| Investments | (32.5M) | (47.0M) | (25.3M) | 124.8M | 118.1M | 124.0M | |
| Change To Netincome | 12.6M | 14.8M | 20.7M | 17.7M | 20.4M | 10.7M | |
| Change Receivables | (45K) | 414K | 102K | (3.3M) | (3.0M) | (2.8M) |
Cara Therapeutic Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cara Therapeutic or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cara Therapeutic's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cara stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.27 | |
β | Beta against NYSE Composite | 5.47 | |
σ | Overall volatility | 7.10 | |
Ir | Information ratio | 0.08 |
Cara Therapeutic Volatility Alert
Cara Therapeutic is displaying above-average volatility over the selected time horizon. Cara Therapeutic is a potential penny stock. Although Cara Therapeutic may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Cara Therapeutic. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Cara instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Cara Therapeutic Fundamentals Vs Peers
Comparing Cara Therapeutic's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cara Therapeutic's direct or indirect competition across all of the common fundamentals between Cara Therapeutic and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cara Therapeutic or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cara Therapeutic's fundamental indicators could also be used in its relative valuation, which is a method of valuing Cara Therapeutic by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cara Therapeutic to competition |
| Fundamentals | Cara Therapeutic | Peer Average |
| Return On Equity | -1.1 | -0.31 |
| Return On Asset | -0.49 | -0.14 |
| Operating Margin | (10.85) % | (5.51) % |
| Current Valuation | (18.84 M) | 16.62 B |
| Shares Outstanding | 54.66 M | 571.82 M |
| Shares Owned By Insiders | 14.58 % | 10.09 % |
| Shares Owned By Institutions | 45.48 % | 39.21 % |
| Number Of Shares Shorted | 2.58 M | 4.71 M |
| Price To Earning | 62.54 X | 28.72 X |
| Price To Book | 0.73 X | 9.51 X |
| Price To Sales | 1.99 X | 11.42 X |
| Revenue | 20.97 M | 9.43 B |
| Gross Profit | (56.14 M) | 27.38 B |
| EBITDA | (121.24 M) | 3.9 B |
| Net Income | (118.51 M) | 570.98 M |
| Cash And Equivalents | 157.51 M | 2.7 B |
| Cash Per Share | 2.93 X | 5.01 X |
| Total Debt | 43.17 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 8.32 X | 2.16 X |
| Book Value Per Share | 1.05 X | 1.93 K |
| Cash Flow From Operations | (92.08 M) | 971.22 M |
| Short Ratio | 3.51 X | 4.00 X |
| Earnings Per Share | (2.19) X | 3.12 X |
| Target Price | 5.23 | |
| Number Of Employees | 55 | 18.84 K |
| Beta | 0.7 | -0.15 |
| Market Capitalization | 38.75 M | 19.03 B |
| Total Asset | 125.84 M | 29.47 B |
| Retained Earnings | (684.75 M) | 9.33 B |
| Working Capital | 90.57 M | 1.48 B |
| Current Asset | 108.93 M | 9.34 B |
| Current Liabilities | 5.27 M | 7.9 B |
Note: Disposition of 30000 shares by Makara Richard of Cara Therapeutic at 18.93 subject to Rule 16b-3 [view details]
Cara Therapeutic Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cara . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cara Therapeutic Buy or Sell Advice
When is the right time to buy or sell Cara Therapeutic? Buying financial instruments such as Cara Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 3.7M | 1.9M | 43.2M | 45.3M | Total Assets | 247.1M | 182.2M | 125.8M | 136.4M |
Use Investing Ideas to Build Portfolios
In addition to having Cara Therapeutic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Publicly traded companies that are involved in real estate development, property maintenance and management of real estate investment trusts (REIT) funds. The Real Estate theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cara Therapeutic Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.387 | Quarterly Revenue Growth (0.08) | Return On Assets (0.49) | Return On Equity (1.10) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.